Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
13/10/2026 21:32
BRIEF-Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases Generate Biomedicines Inc GENB.O:
GENERATE BIOMEDICINES AND ZEALAND PHARMA ENTER COLLABORATION AND LICENSE AGREEMENT TO DEVELOP PROTEIN THERAPEUTICS ENGINEERED WITH AI FOR METABOLIC DISEASES
GENERATE BIOMEDICINES - TO RECEIVE $30 MILLION UPFRONT, UP TO $1.20 BILLION IN MILESTONES, PLUS ROYALTIES
GENERATE BIOMEDICINES - COLLABORATION TO DEVELOP MULTISPECIFIC PROTEIN THERAPEUTICS FOR OBESITY AND METABOLIC DISEASES
GENERATE BIOMEDICINES - TO LEAD RESEARCH; ZEALAND PHARMA TO HANDLE CLINICAL DEVELOPMENT AND COMMERCIALIZATION
GENERATE BIOMEDICINES - CO TO LEAD RESEARCH; ZEALAND PHARMA TO HANDLE CLINICAL DEVELOPMENT AND COMMERCIALIZATION
Source text: ID:nGNX9WNXY0
Further company coverage: GENB.O
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)